Research map: Passenger variants as pan‐clonal markers of pediatric AML: Implications for molecular MRD

Back to the article

Papers in this map

  1. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell · Dominique A. Bonnet · 1997 · 7038 citations · Cited by this paper
  2. Expansion and safety profile of CD28‐costimulated anti‐CD19 CAR T cells in B‐cell lymphoma versus autoimmune disease · 2026 · Related
  3. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours · Xiaotu Ma · 2018 · 967 citations · Cited by this paper
  4. Publication Only · 2026 · Related
  5. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions · Hamid Bolouri · 2017 · 903 citations · Cited by this paper
  6. Polygenic scores in the diagnosis of abnormal complete blood count values · 2026 · Related
  7. Molecular Minimal Residual Disease in Acute Myeloid Leukemia · Mojca Jongen‐Lavrencic · 2018 · 802 citations · Cited by this paper
  8. Real‐world, multi‐omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS) · 2026 · Related
  9. Single-cell mutation analysis of clonal evolution in myeloid malignancies · Linde A. Miles · 2020 · 552 citations · Cited by this paper
  10. From monoclonal to polyfunctional immunotherapy: Reprogramming CAR‐T‐cell therapy with oncolytic viruses in B‐cell malignancies · 2026 · Related
  11. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice · Jean‐Emmanuel Sarry · 2010 · 394 citations · Cited by this paper
  12. Adult TWIST2 ‐high B‐ALL confirms metabolic association but reveals molecular heterogeneity · 2026 · Related
  13. Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse · Jason E. Farrar · 2016 · 174 citations · Cited by this paper
  14. Preclinical evaluation of the ROR1‐targeting antibody–drug conjugates zilovertamab vedotin and VLS‐211 against B‐cell ALL patient‐derived xenografts · 2026 · Related
  15. Genetically distinct leukemic stem cells in human CD34− acute myeloid leukemia are arrested at a hemopoietic precursor-like stage · Lynn Swun Quek · 2016 · 159 citations · Cited by this paper
  16. Persistent BCR::ABL1 ‐positive preleukemic stem cells drive late clonal evolution in Philadelphia chromosome‐positive ALL · 2026 · Related
  17. A new genomic framework to categorize pediatric acute myeloid leukemia · Masayuki Umeda · 2024 · 122 citations · Cited by this paper
  18. EHA Recommendations for preconceptual and antenatal screening and prenatal diagnosis for hemoglobinopathies · 2026 · Related
  19. Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO ‐ AML 2004 study · Anne Maria Tierens · 2016 · 89 citations · Cited by this paper
  20. CAR T‐cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myeloma · 2026 · Related
  21. High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine · Costa Bachas · 2010 · 76 citations · Cited by this paper
  22. 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party · Jacqueline J Cloos · 2025 · 63 citations · Cited by this paper
  23. Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies · Barbara Buldini · 2019 · 47 citations · Cited by this paper
  24. Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia · Tomoyuki N. Tanaka · 2021 · 44 citations · Cited by this paper
  25. Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia · Kristian Løvvik Juul-Dam · 2020 · 39 citations · Cited by this paper
  26. Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines · Vincent H. J. van der Velden · 2024 · 33 citations · Cited by this paper
  27. Patient‐tailored analysis of minimal residual disease in acute myeloid leukemia using next‐generation sequencing · Erik Delsing Malmberg · 2016 · 32 citations · Cited by this paper
  28. Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide Variations · Erik Delsing Malmberg · 2018 · 25 citations · Cited by this paper
  29. Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel · Christian Michel Zwaan · 2025 · 25 citations · Cited by this paper
  30. High-Throughput Multimodal Single-Cell Targeted DNA and Surface Protein Analysis Using the Mission Bio Tapestri Platform · David W. Ruff · 2021 · 23 citations · Cited by this paper
  31. Clinical impact of minimal residual disease in blood and bone marrow of children with acute myeloid leukemia · Seth E. Karol · 2023 · 12 citations · Cited by this paper
  32. What Is Abnormal in Normal Karyotype Acute Myeloid Leukemia in Children? Analysis of the Mutational Landscape and Prognosis of the TARGET-AML Cohort · Morten Krogh Herlin · 2021 · 11 citations · Cited by this paper
  33. Recommendations from the AML molecular MRD expert advisory board · Stuart D. Scott · 2024 · 11 citations · Cited by this paper
  34. Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study · Marketa Kubricanova Zaliova · 2023 · 10 citations · Cited by this paper
  35. Real-world clinical utility of tumor whole-genome sequencing in solid cancers · Jeffrey van Putten · 2026 · 10 citations · Cited by this paper
  36. Untitled · Cited by this paper
  37. Untitled · Cited by this paper

Source: OpenAlex (CC0)